Johnson & Johnson looking to buy eye disease biotech for up to $3.4bn
Johnson & Johnson agreed to buy Texas-based biotech Ollin Biosciences for up to $3.33 billion to expand its eye disease therapies.
Velocity
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
The brief
Johnson & Johnson announced it has agreed to buy the Texas-based biotech Ollin Biosciences for up to $3.33 billion to expand its pipeline of eye disease therapies, according to Endpoints News. The drugmaker stated it will acquire Ollin for $2.2 billion upfront, with the potential for regulatory and commercial milestone payments reaching up to about $1.13 billion. Some reports noted figures up to $3.4 billion, while Yahoo Finance and other outlets cited a Financial Times report mentioning up to $3.4bn.
Established in 2023, Ollin is backed by investment firms ARCH Venture Partners and Mubadala Capital to develop treatments for vision-threatening diseases. Through this acquisition, J&J gains access to an experimental eye disease treatment, boosting its presence in a therapeutic area where it previously maintained a limited footprint despite its large contact lens business. Ollin is developing OLN324, an experimental drug intended to treat diabetic macular edema and wet age-related macular degeneration, which are two leading causes of vision loss.
According to Kip Connor, vice president, ophthalmology disease area stronghold leader at Johnson & Johnson, OLN324 selectively targets two important drivers of retinal disease and has the potential to achieve stronger and more sustained disease control. Ollin reported that in a recent early-stage head-to-head study, the drug showed faster and greater improvements in eye structure and greater vision gains in both diabetic macular edema and wet age-related macular degeneration than Roche's Vabysmo. Ollin's pipeline also includes OLN102, which is currently in preclinical development for thyroid eye disease and Graves' disease.
Ollin previously stated plans to begin late-stage studies testing OLN324 in the second half of this year, having raised $330 million in June to fund those trials. Additionally, Johnson & Johnson said it will enter into a separate agreement with Blackstone Life Sciences. Blackstone will pay $750 million to the drugmaker over multiple years to fund the late-stage development of OLN324, and in turn, Blackstone will be eligible to receive payments and royalties. Endpoints News also noted that last week, Pfizer announced Blackstone would provide up to $1.5 billion through 2028 to help fund the development of an experimental monthly obesity treatment.
Synthesized by PULSE from the headlines below under a strict no-invention contract. ✓ fact-checked: all claims supported by sources Updated 22h ago.
Quick answers
How much is Johnson & Johnson paying for Ollin Biosciences?
J&J is paying $2.2 billion upfront, with potential regulatory and commercial milestone payments of up to about $1.13 billion, bringing the total up to $3.33 billion (some reports cite up to $3.4 billion).
What is the main experimental drug being acquired?
J&J is acquiring OLN324, an experimental drug designed to treat diabetic macular edema and wet age-related macular degeneration.
What is Blackstone Life Sciences' role in the deal?
Blackstone will pay $750 million to the drugmaker over multiple years to fund the late-stage development of OLN324 and will receive payments and royalties in return.
Coverage (20)
- J&J pays $2.2B upfront for Ollin, taps Blackstone to fund eye disease trial BioSpace · 1d ago
- J&J bets $2.2B on Ollin’s vision loss drug BioPharma Dive · 1d ago
- J&J to buy eye disease biotech Ollin Biosciences for up to $3.3 billion CNBC · 2d ago
- Johnson & Johnson to Buy Eye-Disease Biotech Ollin WSJ · 2d ago
- J&J to buy eye disease biotech Ollin Biosciences for up to $3.3B Endpoints News · 2d ago
- Austin biotech startup to be acquired by Johnson & Johnson for $3.3B The Business Journals · 2d ago
- J&J pays $2.2B upfront for Ollin to challenge Roche’s Vabysmo with phase 3 bispecific Fierce Biotech · 2d ago
- Blackstone Life Sciences Announces $750 Million R&D Funding Agreement Business Wire · 2d ago
- J&J strikes $2.2 billion buyout deal for eye disease biotech TradingView · 2d ago
- Johnson & Johnson to Buy Ollin Biosciences for $2.2 Billion WSJ · 2d ago
- Johnson & Johnson to Acquire Ollin Biosciences for Up to $3.33 Billion marketscreener.com · 2d ago
- J&J strikes $2.2 billion buyout deal for eye disease biotech Ollin Biosciences Reuters · 2d ago
- Ollin Biosciences and Its Next-Generation Medicines for Patients with Vision-Threatening Eye Diseases to be Acquired Business Wire · 2d ago
- Johnson & Johnson to acquire Ollin Biosciences and late-stage bispecific antibody with best-in-class potential in ophthalmology Business Wire · 2d ago
- J&J looks to buy Ollin Biosciences for up to $3.4 billion, FT says Yahoo Finance · 2d ago
- Johnson & Johnson looking to buy Ollin Biosciences for up to $3.4 billion, FT says marketscreener.com · 2d ago
- J&J nears $3.4B purchase of eye disease developer Ollin: report FirstWord Pharma · 2d ago
- Johnson & Johnson Eyes A $3.4 Billion Bet On Eye Disease Finimize · 2d ago
- J&J looks to buy Ollin Biosciences for up to $3.4 billion, FT says Reuters · 2d ago
- Johnson & Johnson looking to buy eye disease biotech for up to $3.4bn Financial Times · 2d ago
Topics
Related trends
Biotech Tops The 'Most Bullish Conversations' And Breaks Out
Biotech markets surge in bullish conversations amid major trial outcomes and regulatory updates from key industry players.
Wall Street Races for Megadeals as Countdown Begins on Trump Era
Wall Street dealmakers race to close mega-mergers as a Democratic midterm surge reshapes the regulatory outlook for the remainder of the Trump era.
Moderna raises 2026 outlook as CEO says newer vaccines are gaining traction
Moderna raises its 2026 outlook and swings to a profit as newer vaccines and cancer treatments gain traction.
Novartis cites cases of previously unknown tumors possibly tied to its SMA gene therapy
Novartis reports cases of tumors in children following treatment with its spinal muscular atrophy gene therapy, Zolgensma.
Revolution Medicines’ pancreatic cancer drug has stunning commercial debut
Revolution Medicines' pancreatic cancer drug Rasonque achieves an eye-popping commercial debut, shattering analyst estimates.
Scientists reverse liver cell aging and cut Alzheimer’s-linked protein in half
Recent reporting highlights scientific breakthroughs targeting cellular aging, liver rejuvenation, and amyloid-beta reduction.